Who owns Autolus Therapeutics plc?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of AUTL from SEC Form 13F filings across 83 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 83 institutions disclosed 132.2M shares of Autolus Therapeutics plc worth $212.0M — about 49.7% of shares outstanding; the largest disclosed holder is MAK CAPITAL ONE LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
83
13F holders
$212.0M
value, 2026 filers
49.7%
of shares outstanding (132.2M sh)
9
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of AUTL's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | MAK CAPITAL ONE LLC | 33.6M | $53.8M | 7.5% | 12.6% | 0.0% |
| 2 | Blackstone Inc. | 20.5M | $32.8M | 0.1% | 7.7% | 0.0% |
| 3 | Syncona Portfolio Ltd | 16.6M | $26.6M | 100.0% | 6.3% | 0.0% |
| 4 | ARMISTICE CAPITAL, LLC | 15.0M | $24.0M | 0.3% | 5.6% | -5.1% |
| 5 | Tetragon Partners GP Ltd | 9.5M | $15.2M | 2.4% | 3.6% | 0.0% |
| 6 | SCHRODER INVESTMENT MANAGEMENT GROUP | 7.8M | $12.9M | 0.0% | 2.9% | -17.5% |
| 7 | Frazier Life Sciences Management, L.P. | 4.4M | $7.1M | 0.2% | 1.7% | 0.0% |
| 8 | BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 3.4M | $5.4M | 0.0% | 1.3% | 0.0% |
| 9 | Laurion Capital Management LP | 3.3M | $5.3M | 0.1% | 1.2% | 0.0% |
| 10 | RENAISSANCE TECHNOLOGIES LLC | 2.0M | $3.2M | 0.0% | 0.7% | -13.7% |
| 11 | BANK OF AMERICA CORP /DE/ | 1.6M | $2.6M | 0.0% | 0.6% | -13.0% |
| 12 | BlackRock, Inc. | 1.6M | $2.6M | 0.0% | 0.6% | +8.3% |
| 13 | UBS Group AG | 1.5M | $2.4M | 0.0% | 0.6% | +16.2% |
| 14 | MORGAN STANLEY | 1.3M | $2.0M | 0.0% | 0.5% | +33.9% |
| 15 | MILLENNIUM MANAGEMENT LLC | 1.2M | $2.0M | 0.0% | 0.5% | +498.3% |
| 16 | Cetera Investment Advisers | 1.2M | $1.9M | 0.0% | 0.4% | +2.5% |
| 17 | Balyasny Asset Management L.P. | 972,748 | $1.6M | 0.0% | 0.4% | +0.1% |
| 18 | JPMORGAN CHASE & CO | 913,239 | $1.5M | 0.0% | 0.3% | -2.4% |
| 19 | Alphabet Inc. | 698,262 | $1.1M | 0.0% | 0.3% | 0.0% |
| 20 | CITADEL ADVISORS LLC | 695,890 | $1.1M | 0.0% | 0.3% | +51.5% |
| 21 | Hennion & Walsh Asset Management, Inc. | 451,403 | $722,245 | 0.0% | 0.2% | +2.5% |
| 22 | Privium Fund Management B.V. | 363,430 | $581,488 | 0.1% | 0.1% | 0.0% |
| 23 | EDENTREE ASSET MANAGEMENT Ltd | 300,000 | $477,000 | 0.1% | 0.1% | 0.0% |
| 24 | JANE STREET GROUP, LLC | 299,862 | $479,779 | 0.0% | 0.1% | +22.0% |
| 25 | XTX Topco Ltd | 287,456 | $459,930 | 0.0% | 0.1% | +409.6% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.